TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Federal prosecutors charged Swapnadip Roy and Vicky Ramancha with conspiracy and smuggling in connection with an alleged counterfeit Ozempic distribution scheme. The indictment alleges they obtained products from unauthorized sources in China and sold them to U.S. distributors between July 2023 and April 2024; both defendants are presumed innocent.
Federal prosecutors have charged Swapnadip Roy, 33, and Vicky Ramancha, 37, in an alleged scheme to distribute counterfeit Ozempic in the United States. The U.S. Attorney’s Office for the Middle District of Florida and the Justice Department’s Criminal Division announced conspiracy and smuggling charges on September 29, 2026, following an investigation assisted by the FDA’s Office of Criminal Investigations.
According to court documents cited in the FDA announcement, Roy and Ramancha allegedly obtained counterfeit Ozempic from unauthorized sources in China between July 2023 and April 2024. The indictment alleges the products were then sold to other alleged co-conspirators and distributors in the United States at deeply discounted prices.
The alleged counterfeit products included packaging, package inserts, pen labels and needles designed to make them appear to be authentic, manufacturer-authorized Ozempic. Prosecutors allege the presentation was intended to deceive downstream customers, including pharmacies and patients. The announcement does not establish that every product attributed to the alleged scheme reached patients or identify specific affected purchasers.
The FDA said its public safety alerts about counterfeit Ozempic began in December 2023. Court documents allege Roy, Ramancha and their co-conspirators continued distributing counterfeit products after the agency’s seizure and public warning that month. The charges are allegations, not findings of guilt; the defendants are presumed innocent unless proven guilty beyond a reasonable doubt.
Risks to the Ozempic Supply Chain
The case concerns an alleged effort to move counterfeit prescription medicine through U.S. distribution channels, where deceptive labels and packaging could make it harder for buyers to distinguish a fake product from an authorized one. That matters to patients, pharmacies and health care providers who rely on legitimate supply chains to know what medicine they are handling or dispensing.
The FDA’s account alleges that the products included not only counterfeit packaging but also pen labels and needles. The agency did not specify in this announcement what the counterfeit pens contained, whether their contents were tested, or whether anyone was harmed. Those limits matter: the alleged risk stems from the products’ counterfeit status and uncertain provenance, but the release does not document particular patient outcomes.
The allegations also point to the cross-border nature of the suspected activity: products allegedly came from sources in China and were sold to U.S. distributors. The FDA says it worked with federal partners on the investigation, showing how criminal enforcement can address suspected activity spanning supply sources and domestic resale. The case may provide information about how counterfeit products were marketed and moved, but the charges alone do not establish the defendants’ guilt or the full reach of the alleged network.
As an affiliate, we earn on qualifying purchases.
FDA Alerts Preceded the Charges
The alleged distribution period ran from July 2023 through April 2024, according to court documents described by the FDA. The agency says it began issuing public safety alerts in December 2023, while the indictment alleges the distribution continued after a seizure and warning that month. The FDA announcement does not give the date of the seizure or detail its scope.
Ozempic is a prescription medicine, and products represented as genuine but obtained outside authorized channels can create uncertainty about their identity and handling. In this case, the FDA’s statement focuses on alleged counterfeit presentation and distribution, rather than reporting test results or specifying what ingredients were in the seized or distributed products. The investigation involved the FDA’s Office of Criminal Investigations, while the charges were announced by federal prosecutors in Florida and the Justice Department’s Criminal Division.
The FDA encourages reports of suspected counterfeit or tampered medicines, including products sold online. Its announcement directs consumers and other parties to use the agency’s “Report a problem” channel. That general reporting notice is separate from the criminal allegations against Roy and Ramancha.
““Infiltrating the American drug supply with counterfeit products isn’t just a crime — it’s also a direct threat to public health and patient safety.””
— Kyle Diamantas, acting FDA commissioner of food and drugs
As an affiliate, we earn on qualifying purchases.
Evidence and Product Reach Still Unknown
The FDA announcement does not provide the indictment text, detail the evidence supporting each charge, or say whether Roy or Ramancha have entered pleas. It also does not identify the quantity of alleged counterfeit Ozempic, the specific U.S. distributors involved, or how many products may have reached pharmacies or patients.
The agency did not report what the counterfeit products contained, whether laboratory testing was performed, or whether any patient injury has been linked to them. The exact status and scope of the December 2023 seizure are also not described. These points remain unconfirmed in the available announcement; the court process may provide further information. The allegations should not be treated as proven facts.
As an affiliate, we earn on qualifying purchases.
Federal Court Proceedings Ahead
The case will proceed through the federal court system, where prosecutors must prove the charges beyond a reasonable doubt. The FDA release does not provide a schedule for hearings, identify any upcoming court date, or say when further filings may become public. The defendants’ responses and the court’s next steps were not stated in the announcement.
Separately, the FDA says suspected counterfeit or tampered medicines can be reported through its consumer reporting channel. Pharmacies, health care providers and consumers who believe they have encountered a suspect product can contact the agency; that general guidance does not confirm that any particular product is connected to this case.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who has been charged?
Swapnadip Roy, 33, and Vicky Ramancha, 37, both described by the FDA as Indian nationals, were charged by federal prosecutors. They are accused of conspiracy and smuggling related to an alleged counterfeit prescription drug distribution scheme.
What does the indictment allege?
Court documents described by the FDA allege that Roy and Ramancha obtained counterfeit Ozempic from unauthorized sources in China and sold it to U.S. distributors between July 2023 and April 2024. The products allegedly used counterfeit packaging and components to appear authentic.
Have the charges been proven?
No. The FDA says an indictment is an allegation, and both defendants are presumed innocent unless prosecutors prove their guilt beyond a reasonable doubt in court.
Did the FDA report patient injuries?
The September 29 announcement does not report patient injuries or say what the alleged counterfeit products contained. It also does not say whether any patient received a product connected to the alleged scheme.
How can suspected counterfeit medicine be reported?
The FDA directs consumers and others to report suspected counterfeit or tampered medicines through its “Report a problem” channel. The agency’s general reporting guidance does not establish that a reported product is connected to this case.
Source: primary
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
